BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B

Q2 Report April-June 2023

Stockholm, July 12, 2023

Gunilla Osswald, PhD, CEO

Anders Martin-Löf, CFO

BIOARCTIC

Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- Investigational uses of an agent in development included in this presentation are not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BIOARCTIC

LEQEMBI® (lecanemab) approved in the US – the world's first fully approved disease-modifying treatment for AD

- On June 9, the FDA Advisory Committee voted unanimously confirming the clinical benefit of LEQEMBI
- On July 6, the FDA granted Eisai traditional approval for LEQEMBI for the treatment of Alzheimer's disease
- The CMS announced that Medicare will provide broad coverage of LEQEMBI
  - according to the FDA approved label
  - provided that real-world evidence is collected in an existing easy-to-use patient registry



BIOARCTIC

Lecanemab has the potential to become the first anti-Aβ antibody to receive full approval globally

USA ✓

FDA granted Leqembi traditional approval July 6, 2023

CMS provided broader Medicare coverage following FDA traditional approval July 6, 2023

VHA provided coverage for Leqembi March 13, 2023

Eisai plans to submit s.c. formulation and maintenance dosing applications by Q1 2024

Japan

Marketing authorization application submitted on January 16, 2023.

Granted priority review on January 30, 2023

Expected PMDA decision September 2023

EU

Marketing authorization application submitted on January 9, 2023

Accepted for a standard review on January 26, 2023

Expected EMA decision Q1 2024

China

Initiated Biologics License Application in December 2022.

Granted priority review on February 28, 2023

Expected NMPA decision Q1 2024

Rest of World

Canada: Submission accepted May 14, 2023

Great Britain: Application submitted May 19, 2023. ILAP designation

South Korea: Application submitted June 7, 2023

FDA – Food & Drug Administration
CMS – Prescription Drug User Fee Act
VHA – Veterans' Health Administration
PMDA – Pharmaceuticals and Medical Devices Agency
EMA – European Medicines Agency
NMPA – National Medical Products Administration
s.c. – subcutaneous

BIOARCTIC

Global estimates for future early AD patients treated with disease modifying treatments (DMTs) offer substantial room for growth



Eisai estimate 2032: ~240 million

Opportunities that could increase patient access:

- Patient awareness and less stigma
- Education at primary care
- Access to specialist care
- Improved diagnostics
- Subcutaneous formulation

Eisai has forecasted 10,000 patients on LEQEMBI by the end of Q1 2024

Eisai estimate 2032: ~3 million

Note: Size of circles are not indicative of actual proportions
Estimates based on internal calculations (Eisai/IQVIA)

BIOARCTIC

Partnership model to de-risk clinical development and optimize commercialization opportunity

Alzheimer's disease

Partner track record

Eisai

Discovered and developed world's best-selling medicine for symptoms in Alzheimer's disease

Industry-leading pipeline in dementia area

Aricept
donepezil HCl tablet

Used to treat confusion (dementia) related to Alzheimer's disease

Collaboration and license

Milestones of up to

MEUR 101

remains to be received

Royalties
High single digit %

BioArctic retains rights to lecanemab in other indications and option to market in the Nordics

The next potential milestones relate to approvals in Japan and the EU

BIOARCTIC

Attractive and well-balanced project portfolio

	Project	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory & Market
ALZHEIMER'S DSEASE	Lecanemab (BAN2401) *(Clarity AD)*	Eisai[1]	Early Alzheimer's disease[2]					
	Lecanemab (BAN2401) *(AHEAD 3-45)*	Eisai[1]	Preclinical (asymptomatic) Alzheimer's disease[3]					
	BAN2401 back-up	Eisai						
	BAN1503 (Trunc Abeta)							
	AD-BT2802							
	AD-BT2803 (Trunc Abeta with BT)							
	AD2603							
PARKINSON'S DISEASE	BAN0805 (alpha-synuclein)							
	PD1601 (alpha-synuclein)							
	PD1602 (alpha-synuclein)							
	PD-BT2238 (alpha-synuclein with BT)							
OTHER CNS DISORDERS	Lecanemab (BAN2401)				Down's syndrome[4], Traumatic brain injury[4]			
	ND3014 (TDP-43)			ALS				
	ND-BT3814 (TDP-43 with BT)			ALS				
	GD-BT6822 (GCase with BT)			Gaucher disease				
BLOOD BRAIN BARRIER	Brain Transporter (BT) technology platform							

1) Partner with Eisai for lecanemab for treatment of Alzheimer's disease since 2007. Eisai entered partnership with Biogen regarding BAN2401 (lecanemab) in 2014
2) Mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease
3) Normal cognitive function with intermediate or elevated levels of amyloid in the brain
4) Dementia and cognitive impairment associated with Down's syndrome and with traumatic brain injury

BIOARCTIC

Financial Summary

Operating expenses 2023 within guidance



- Net revenues were SEK 3 M (4) for Q2 and SEK 397 M for the first half of the year
  - Three Q1 milestone payments of SEK 391 M (€ 35 M) in total
- Revenues will become less lumpy when royalties increase

- Operating expenses increased to SEK 104 M (50) in Q2 and SEK 200 M (98) Jan-Jun
  - Personnel costs increased to SEK 72 M (23) in Q2 mainly due to non-recurring effects,
  - Repurchase of stock options & other stock options costs with related social security provisions
- Costs will increase longer term
  - Build-up of commercial organization
  - Progression of project portfolio

- Operating loss was SEK 101 M (46) for Q2, profit of SEK 200 M (loss: 90) for the first half of the year

Full-year operating expense guidance reiterated:
SEK 330 – 380 M for 2023, compared to SEK 246 M in 2022

Strong financial position

Cash Balance (SEK M)



- Cash balance amounted to SEK 1,042 M at the end of the second quarter

Cash Flow From Operating Activities (SEK M)



- Operating cash flow was a negative SEK 64 M (neg. 46) in Q2, positive SEK 235 M (neg. 85) for the first half of the year

Net Result (SEK M)



- Net loss for Q2 was SEK 102 M (46), net profit of SEK 192 M (loss: 90) for the first half of the year

Milestones from Eisai of € 35 M in Q1 2023 further strengthened the financial position

BIOARCTIC

Upcoming news flow and closing remarks

Upcoming news flow



PDUFA – Prescription Drug User Fee Act
CMS – Centers for Medicare & Medicaid Services
s.c. – subcutaneous

”

BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients with neurodegenerative diseases.

BIOARCTIC

IR team

GUNILLA OSSWALD, CEO	ANDERS MARTIN-LÖF, CFO	OSKAR BOSSON, VP COMMUNICATIONS & IR	CECILIA LANNEBO, DIRECTOR IR
			

To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com

Contact:
Oskar Bosson,
VP Communications & IR
+46 704 10 71 80
ir@bioarctic.se

Next Report:
Q3 Report
Jul-Sep 2023
on November 8, 2023